ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on October 31, 2024. The report discloses a material change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate governance event rather than a financial performance report.
Material Changes
- Change in Certifying Accountant: The Company engaged KPMG LLP as its new independent registered public accounting firm.
- Effective Date: The engagement is effective upon the filing of the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024.
- Scope of Engagement: KPMG will audit the consolidated financial statements for the fiscal year ending December 31, 2024.
- Consultation History: The Company confirmed no consultations with KPMG regarding accounting principles or disagreements during the fiscal years ended December 31, 2023 and 2022, or the interim period through October 31, 2024.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the auditor change. The anticipated filing date for the 2024 Annual Report on Form 10-K is on or before March 3, 2025.
Key Facts for Investor Verification
- Verify the identity of the previous independent registered public accounting firm to understand the context of the change.
- Review the upcoming Form 10-Q for the quarter ended September 30, 2024, to confirm the effective date of the new auditor's engagement.
- Monitor the Form 10-K filing (due by March 3, 2025) for the first audited financial statements prepared under KPMG's supervision.
- Confirm that no disagreements or reportable events occurred with the prior auditor, as stated in the filing.